3-(1H-苯并[d]咪唑-2-基)哌啶-1-羧酸叔丁酯 | 1229000-10-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 3-(1H-苯并[d]咪唑-2-基)哌啶-1-羧酸叔丁酯
• 中文别名: 2-(N-BOC-哌啶-3-基)-1H-苯并咪唑
• 英文名称: tert-butyl 3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate
• 英文别名: (R)-tert-butyl 3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate；2-(N-Boc-piperidin-3-yl)-1H-benzoimidazole；tert-butyl 3-(1H-benzimidazol-2-yl)piperidine-1-carboxylate
• CAS: 1229000-10-5
• 化学式: C₁₇H₂₃N₃O₂
• 分子量: 301.389
• InChiKey: NQJXCURWALTMNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  58.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-(1H-苯并[d]咪唑-2-基)哌啶-1-羧酸叔丁酯 在 potassium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-[(4-fluorophenyl)methyl]-2-[(3R)-piperidin-3-yl]benzimidazole
  参考文献：
  名称：

  Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: Identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia

  摘要：

  The structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles, 2-morpholine and 2-thiomorpholin-2-yl-1H-benzimidazoles are described. In the lead optimization process, the pK(a) and/or logP of benzimidazole analogs were reduced either by attachment of polar substituents to the piperidine nitrogen or incorporation of heteroatoms into the piperidine heterocycle. Compounds 9a and 9b in the morpholine series and 10g in the thiomorpholine series demonstrated improved selectivity and CNS profiles compared to lead compound 2 and these are potential candidates for evaluation as sedative hypnotics. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.115
• 作为产物：
  描述：

  1-BOC-哌啶-3-羧酸 在 盐酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 3-(1H-苯并[d]咪唑-2-基)哌啶-1-羧酸叔丁酯
  参考文献：
  名称：

  [EN] COMPOUNDS AS INHIBITORS OF RENIN
  [FR] COMPOSÉS INHIBITEURS DE RÉNINE

  摘要：

  本发明涉及一般式（1）的新型肾素抑制剂，涉及其合成中所涉及的新型中间体，其药学上可接受的盐以及含有它们的药物组合物。本发明还涉及制备一般式（1）化合物的过程，它们的互变异构体形式，其药学上可接受的盐，含有它们的药物组合物，以及其合成中所涉及的新型中间体。

  公开号：

  WO2013084241A1

文献信息

• [EN] COMPOUNDS AS INHIBITORS OF RENIN<br/>[FR] COMPOSÉS INHIBITEURS DE RÉNINE
  申请人：CADILA HEALTHCARE LTD

  公开号：WO2013084241A1

  公开（公告）日：2013-06-13

  The present invention relates to novel renin inhibitors of general formula (1), novel intermediates involved in their synthesis, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to processes for preparing compounds of general formula (1), their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.

  本发明涉及一般式（1）的新型肾素抑制剂，涉及其合成中所涉及的新型中间体，其药学上可接受的盐以及含有它们的药物组合物。本发明还涉及制备一般式（1）化合物的过程，它们的互变异构体形式，其药学上可接受的盐，含有它们的药物组合物，以及其合成中所涉及的新型中间体。
• Renin inhibitors
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US08138168B1

  公开（公告）日：2012-03-20

  The invention relates to compounds having the formulae: wherein the variables are as defined herein. The invention further relates to methods of making and using these compounds, and pharmaceutical compositions, kits and articles of manufacture comprise the compounds.

  本发明涉及具有以下式子的化合物：其中变量如本文所定义。本发明还涉及制备和使用这些化合物的方法，以及包含这些化合物的制药组合物、工具包和制造物。
• Specific inhibitors of methionyl-tRNA synthetase
  申请人：UNIVERSITY OF WASHINGTON

  公开号：US10913736B2

  公开（公告）日：2021-02-09

  The present disclosure is generally directed to compositions useful in the inhibition of MetRS and methods for treating diseases that are ameliorated by the inhibition of MetRS.

  本公开总体上涉及可用于抑制 MetRS 的组合物，以及通过抑制 MetRS 改善疾病的治疗方法。
• The discovery and structure–activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia
  作者：Karine Lavrador-Erb、Satheesh Babu Ravula、Jinghua Yu、Said Zamani-Kord、Wilna J. Moree、Robert E. Petroski、Jianyun Wen、Siobhan Malany、Samuel R.J. Hoare、Ajay Madan、Paul D. Crowe、Graham Beaton

  DOI：10.1016/j.bmcl.2010.03.027

  日期：2010.5

  A series of 2-(3-aminopiperidine)-benzimidazoles were identified as selective H-1-antihistamines for evaluation as potential sedative hypnotics. Representative compounds showed improved hERG selectivity over a previously identified 2-aminobenzimidazole series. While hERG activity could be modulated via manipulation of the benzimidazole N1 substituent, this approach led to a reduction in CNS exposure for the more selective compounds. One example, 9q, retained a suitable selectivity profile with CNS exposure equivalent to known centrally active H-1-antihistamines. (C) 2010 Elsevier Ltd. All rights reserved.
• SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE
  申请人：UNIVERSITY OF WASHINGTON

  公开号：US20170275279A1

  公开（公告）日：2017-09-28

  The present disclosure is generally directed to compositions useful in the inhibition of MetRS and methods for treating diseases that are ameliorated by the inhibition of MetRS.